<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34536404</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.</ArticleTitle><Pagination><StartPage>821</StartPage><EndPage>831</EndPage><MedlinePgn>821-831</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(21)00242-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(21)00242-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is an urgent unmet need for new therapies in amyotrophic lateral sclerosis. In a clinical study with healthy volunteers, levosimendan, a calcium sensitiser, was shown to improve neuromechanical efficiency and contractile function of the human diaphragm. We aimed to evaluate the safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis, with a focus on respiratory function.</AbstractText><AbstractText Label="METHODS">The REFALS study is a randomised, double-blind, placebo-controlled phase 3 trial at 99 amyotrophic lateral sclerosis specialist centres in 14 countries worldwide. People with amyotrophic lateral sclerosis were eligible for participation if they were at least 18 years of age and had a sitting slow vital capacity (SVC) of 60-90% predicted. Participants were randomly assigned (2:1) by interactive web-response system to receive either levosimendan or placebo. The capsules for oral administration were identical in appearance to maintain blinding of participants and investigators. The primary endpoint was the change from baseline in supine SVC at 12 weeks, assessed as the percentage of predicted normal sitting SVC. The key secondary endpoint was the combined assessment of function and survival (CAFS) up to 48 weeks. Analyses were done in the intention-to-treat population, comprising all participants who were randomly assigned. This trial is registered at ClinicalTrials.gov (NCT03505021) and has been completed. An extension study (REFALS-ES; NCT03948178) has also been completed, but will be reported separately.</AbstractText><AbstractText Label="FINDINGS">Between June 21, 2018, and June 28, 2019, 871 people were screened for the study, of whom 496 were randomly assigned either levosimendan (n=329) or placebo (n=167). Participants were followed up between June 27, 2018 and June 26, 2020, for a median duration of 50&#xb7;1 (IQR 37&#xb7;5-51&#xb7;1) weeks. The median duration of treatment was 47&#xb7;9 (IQR 26&#xb7;4-48&#xb7;1) weeks. Change from baseline in supine SVC at 12 weeks was -6&#xb7;73% with levosimendan and -6&#xb7;99% with placebo, with no significant difference between the treatments (estimated treatment difference 0&#xb7;26%, 95% CI -2&#xb7;03 to 2&#xb7;55, p=0&#xb7;83). Similarly, at week 48, CAFS did not differ between treatment groups (least squares mean change from baseline 10&#xb7;69, 95% CI -15&#xb7;74 to 37&#xb7;12; nominal p value=0&#xb7;43). The most frequent adverse events were increased heart rate (106 [33%] of 326 receiving levosimendan vs 12 [7%] of 166 receiving placebo), fall (85 [26%] vs 48 [29%]), headache (93 [29%] vs 36 [22%]), and dyspnoea (59 [18%] vs 32 [19%]). 33 (10%) participants allocated levosimendan and 20 (12%) assigned placebo died during the trial, mainly due to respiratory failure or progression of amyotrophic lateral sclerosis.</AbstractText><AbstractText Label="INTERPRETATION">Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo. The possibility of a clinically relevant subgroup of responsive individuals requires further evaluation.</AbstractText><AbstractText Label="FUNDING">Orion Corporation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA, USA. Electronic address: cudkowicz.merit@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Unit and ALS clinic, Montreal Neurological Institute and Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medizinische Hochschule Hannover, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Utrecht, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Valtteri V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Orion Corporation, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarapohja</LastName><ForeName>Toni</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Orion Corporation, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuoppam&#xe4;ki</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Orion Corporation, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garratt</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Orion Corporation, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, and Department of Neurology, King's College Hospital, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REFALS investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03948178</AccessionNumber><AccessionNumber>NCT03505021</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Neurol. 2021 Oct;20(10):775-777</RefSource><PMID Version="1">34536395</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Nov;17(11):660</RefSource><PMID Version="1">34594004</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests MC reports consultancy fees from Biohaven Pharmaceuticals, Eli Lilly, Orion Corporation, Revelescio, Wave Pharmaceuticals, Mitsubishi Tanabe Pharma, Anelixis, Aclipse, Cytokinetics, Avexis, Sunovian, Disarm, ALS Pharmaceuticals, RRD, Biogen, Takeda, outside the submitted work. AG reports personal fees from Mitsubishi Tanabe Pharma America, Sanofi Genzyme, ALS Pharma, AB Sciences, Biogen, Novartis, CSL Behring, Anavex, Avexis, Alexion, Revalesio, Roche, Cytokinetics, Orion Corporation, and Akcea, outside the submitted work. NM reports personal fees from Orion Corporation, during the conduct of the study; personal fees from Massachusetts General Hospital, Cytokinetics, Amylyx, and Orphazyme, outside the submitted work; and clinical trial site principle investigator fees from Biogen Idec, Medicinova, Anelixis, Apellis, and Helixmith. SP reports grants from the German Neuromuscular Society, Federal Ministry of Education and Research, German Israeli Foundation for scientific research and development, and EU Joint Programme for Neurodegenerative Disease Research; and speaker or medical expert honoraria from Cytokinetics, Desitin Pharma, Biogen, Novartis, Teva Pharmaceuticals, and Roche, outside of the submitted work. LvdB is on the advisory board Orion, with no financial compensation. LvdB reports personal fees from Denali, Calico, Biogen, Ferrer, and Orphazyme; and grants from Takeda, outside the submitted work. VVA, TS and CG are Employees of Orion Corporation; MK is an employee of Orion Corporation and owns Orion Corporation stocks. AA-C reports non-financial support from Orion Corporation, during the conduct of the study; consultancy fees from Mitsubishi Tanabe Pharma, Biogen Idec, Cytokinetics, Wave Pharmaceuticals, Apellis, Amylyx, Novartis, and Eli Lilly, outside the submitted work.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathers</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Needham</LastName><ForeName>Merrilee</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf6;scher</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitrovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rath</LastName><ForeName>Jakob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damme</LastName><ForeName>Philip Van</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Bleecker</LastName><ForeName>Jan L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delstanche</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matte</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dionne</LastName><ForeName>Annie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turnbull</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laaksovirta</LastName><ForeName>Hannu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jokela</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tapiola</LastName><ForeName>Tero</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soriani</LastName><ForeName>Marie-H&#xe9;l&#xe8;ne</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gro&#xdf;kreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boentert</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrank</LastName><ForeName>Berthold</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Untucht</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chio'</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inghilleri</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mora Pardina</LastName><ForeName>Jes&#xfa;s S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrero Munoz</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xe1;zquez Costa</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguera Morales</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varona</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johansson</LastName><ForeName>Rune</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radunovic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaibani</LastName><ForeName>Aziz</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vu</LastName><ForeName>Tuan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scelsa</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sivakumar</LastName><ForeName>Kumaraswamy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waheed</LastName><ForeName>Waqar</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heitzman</LastName><ForeName>Daragh</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rana</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajroud-Driss</LastName><ForeName>Senda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayat</LastName><ForeName>Elham</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lange</LastName><ForeName>Dale J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Brent</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felice</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulley</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwan</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burford</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Chafic</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levine</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fee</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caress</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quick</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bromberg</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacomis</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezania</LastName><ForeName>Kourosh</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guliani</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goslin</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34536404</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00242-8</ArticleId><ArticleId IdType="pii">S1474-4422(21)00242-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>